Literature DB >> 22897845

A new role for PHD in chemotherapy.

Rui-hua Xu1, Peng Huang.   

Abstract

Enhancing therapeutic activity against cancer cells and minimizing toxic effects on normal cells are critical elements in chemotherapy. In this issue of Cancer Cell, Leite de Oliveira and colleagues reveal a previously unrecognized role of a prolyl hydroxylase domain in promoting drug delivery to tumors and reducing toxicity in normal organs.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22897845      PMCID： PMC3422509          DOI： 10.1016/j.ccr.2012.07.013

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  8 in total

1.  Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs.

Authors:  Astrid A M Van der Veldt; Mark Lubberink; Idris Bahce; Maudy Walraven; Michiel P de Boer; Henri N J M Greuter; N Harry Hendrikse; Jonas Eriksson; Albert D Windhorst; Pieter E Postmus; Henk M Verheul; Erik H Serné; Adriaan A Lammertsma; Egbert F Smit
Journal:  Cancer Cell       Date:  2012-01-17       Impact factor: 31.743

Review 2.  Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases.

Authors:  Peter Carmeliet; Rakesh K Jain
Journal:  Nat Rev Drug Discov       Date:  2011-06       Impact factor: 84.694

Review 3.  Prolyl 4-hydroxylase.

Authors:  Kelly L Gorres; Ronald T Raines
Journal:  Crit Rev Biochem Mol Biol       Date:  2010-04       Impact factor: 8.250

4.  Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance.

Authors:  Elizabeth S Nakasone; Hanne A Askautrud; Tim Kees; Jae-Hyun Park; Vicki Plaks; Andrew J Ewald; Miriam Fein; Morten G Rasch; Ying-Xim Tan; Jing Qiu; Juwon Park; Pranay Sinha; Mina J Bissell; Eirik Frengen; Zena Werb; Mikala Egeblad
Journal:  Cancer Cell       Date:  2012-04-17       Impact factor: 31.743

5.  Prolyl hydroxylase domain protein 2 (PHD2) mediates oxygen-induced retinopathy in neonatal mice.

Authors:  Li-Juan Duan; Kotaro Takeda; Guo-Hua Fong
Journal:  Am J Pathol       Date:  2011-04       Impact factor: 4.307

Review 6.  High interstitial fluid pressure - an obstacle in cancer therapy.

Authors:  Carl-Henrik Heldin; Kristofer Rubin; Kristian Pietras; Arne Ostman
Journal:  Nat Rev Cancer       Date:  2004-10       Impact factor: 60.716

7.  Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization.

Authors:  Massimiliano Mazzone; Daniela Dettori; Rodrigo Leite de Oliveira; Sonja Loges; Thomas Schmidt; Bart Jonckx; Ya-Min Tian; Anthony A Lanahan; Patrick Pollard; Carmen Ruiz de Almodovar; Frederik De Smet; Stefan Vinckier; Julián Aragonés; Koen Debackere; Aernout Luttun; Sabine Wyns; Benedicte Jordan; Alberto Pisacane; Bernard Gallez; Maria Grazia Lampugnani; Elisabetta Dejana; Michael Simons; Peter Ratcliffe; Patrick Maxwell; Peter Carmeliet
Journal:  Cell       Date:  2009-02-12       Impact factor: 41.582

8.  Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia.

Authors:  Wan Zhang; Dunyaporn Trachootham; Jinyun Liu; Gang Chen; Helene Pelicano; Celia Garcia-Prieto; Weiqin Lu; Jan A Burger; Carlo M Croce; William Plunkett; Michael J Keating; Peng Huang
Journal:  Nat Cell Biol       Date:  2012-02-19       Impact factor: 28.824
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.